The (Near) Equivalence of Cost—Effectiveness and Cost-Benefit AnalysesFact or Fallacy?

被引:0
|
作者
Cam Donaldson
机构
[1] University of Aberdeen,Health Economics Research Unit
来源
PharmacoEconomics | 1998年 / 13卷
关键词
Adis International Limited; Economic Evaluation; Streptokinase; Alteplase; Advanced Ovarian Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
There has been much recent debate in the health economics literature as to the (near) equivalence of cost—benefit analysis (CBA) and cost—effectiveness analysis (CEA). The aim of this paper is to demonstrate that whether such a (near) equivalence exists depends on whether one defines economic evaluations as ‘CBA’ or ‘CEA’ on the basis of either what is measured or what question the analyst is seeking to answer. The former basis of definition is popular within the ‘decision science’ approach to economic evaluation, but does not seem to have any theoretical support. If the latter, more theoretically correct, basis is accepted, there is no longer a case for the (near) equivalence of CBA and CEA.
引用
收藏
页码:389 / 396
页数:7
相关论文
共 50 条